Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population. The Study of Health in Pomerania (SHIP)

Atherosclerosis

Volumn 245, Issue , 2016, Pages 123-131

  Markus, Marcello Ricardo Paulista ^a,b,c   Meffert, Peter J ^a   Baumeister, Sebastian Edgar ^a,d   Lieb, Wolfgang ^e   Siewert, Ulrike ^a   Schipf, Sabine ^a,c   Koch, Manja ^e,f   Kors, Jan A ^g   Felix, Stephan Burkhard ^a,b   Dörr, Marcus ^a,b   Targher, Giovanni ^h   Völzke, Henry ^a,b,c  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h University and Azienda Ospedaliera Universitaria Integrata of Verona   (Italy)

Author keywords

Atrial fibrillation; Hepatic steatosis; Liver enzymes; Non alcoholic fatty liver disease; Population based study; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; DISEASE ASSOCIATION; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; FATTY LIVER; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; ENZYMOLOGY; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GERMANY; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84951304830     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.023     Document Type: Article

References (50)

1. Targher G., Mantovani A., Pichiri I., Rigolon R., Dauriz M., Zoppini G., Morani G., Vassanelli C., Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin. Sci. (Lond) 2013, 125(6):301-309.
2. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013, 10(6):330-344.
3. Fan J.G., Li F., Cai X.B., Peng Y.D., Ao Q.H., Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 2007, 22(7):1086-1091.
4. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30(8):2119-2121.
5. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363(14):1341-1350.
6. Volzke H., Robinson D.M., Kleine V., Deutscher R., Hoffmann W., Ludemann J., Schminke U., Kessler C., John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J. Gastroenterol. 2005, 11(12):1848-1853.
7. Ballestri S., Lonardo A., Bonapace S., Byrne C.D., Loria P., Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(7):1724-1745.
8. Markus M.R., Baumeister S.E., Stritzke J., Dorr M., Wallaschofski H., Volzke H., Lieb W. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler. Thromb. Vasc. Biol. 2013, 33(7):1690-1695.
9. Alonso A., Misialek J.R., Amiin M.A., Hoogeveen R.C., Chen L.Y., Agarwal S.K., Loehr L.R., Soliman E.Z., Selvin E. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 2014, 100(19):1511-1516.
10. Dessein P.H., Woodiwiss A.J., Joffe B.I., Norton G.R. Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovasc Disord. 2007, 7:31.
11. Andrade J., Khairy P., Dobrev D., Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ. Res. 2014, 114(9):1453-1468.
12. Sinner M.F., Wang N., Fox C.S., Fontes J.D., Rienstra M., Magnani J.W., Vasan R.S., Calderwood A.H., Pencina M., Sullivan L.M., et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am. J. Cardiol. 2013, 111(2):219-224.
13. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Rodella S., Zoppini G., Mantovani W., Barbieri E., Byrne C.D. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013, 8(2):e57183.
14. John U., Greiner B., Hensel E., Ludemann J., Piek M., Sauer S., Adam C., Born G., Alte D., Greiser E., et al. Study of Health in Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz. Praventivmed 2001, 46(3):186-194.
15. Volzke H., Alte D., Schmidt C.O., Radke D., Lorbeer R., Friedrich N., Aumann N., Lau K., Piontek M., Born G., et al. Cohort profile: the study of health in Pomerania. Int. J. Epidemiol. 2011, 40(2):294-307.
16. Baumeister S.E., Friedrich N., Schmidt C.O., Volzke H., Nauck M., Hoffmann W., Flessa S., Marschall P., Wallaschofski H. Association of IGF-I and IGFBP-3 with health care costs and hospitalization: results from a prospective observational study. Growth Horm. IGF Res. 2011, 21(2):89-95.
17. Baumeister S.E., Volzke H., Marschall P., John U., Schmidt C.O., Flessa S., Alte D. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008, 134(1):85-94.
18. Schwarz S., Obst A., Schwahn C., Volzke H., Schmidt C.O., Dorr M., Felix S.B., Doren M. Menopausal hormone therapy does not play a major role in left ventricular hypertrophy. Maturitas 2010, 66(2):212-218.
19. Volzke H., Alte D., Ittermann T., Schmidt C.O., Rettig R., Mayerle J., Lowenfels A.B., Lerch M.M., Nauck M. Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases. Liver Int. 2011, 31(7):985-993.
20. Haring R., Feng Y.S., Moock J., Volzke H., Dorr M., Nauck M., Wallaschofski H., Kohlmann T. Self-perceived quality of life predicts mortality risk better than a multi-biomarker panel, but the combination of both does best. BMC Med. Res. Methodol. 2011, 11:103.
21. Troitzsch P., Paulista Markus M.R., Dorr M., Felix S.B., Junger M., Schminke U., Schmidt C.O., Volzke H., Baumeister S.E., Arnold A. Psoriasis is associated with increased intima-media thickness-the Study of Health in Pomerania (SHIP). Atherosclerosis 2012, 225(2):486-490.
22. Haring R., Baumeister S.E., Lieb W., von Sarnowski B., Volzke H., Felix S.B., Nauck M., Wallaschofski H. Glycated hemoglobin as a marker of subclinical atherosclerosis and cardiac remodeling among non-diabetic adults from the general population. Diabetes Res. Clin. Pract. 2014, 105(3):416-423.
23. Levey A.S., Greene T., Kusek J.W., Beck G.J. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J. Am. Soc. Nephrol. 2000, 11. (A0828).
24. 2. Am. J. Kidney Dis. 2010, 56(3):486-495.
25. Volzke H., Nauck M., Rettig R., Dorr M., Higham C., Brabant G., Wallaschofski H. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur. J. Endocrinol. 2009, 161(5):705-713.
26. van Bemmel J.H., Kors J.A., van Herpen G. Methodology of the modular ECG analysis system MEANS. Methods Inf. Med. 1990, 29(4):346-353.
27. Reffelmann T., Dorr M., Volzke H., Kors J., Ruppert J., Robinson D., Felix S.B. Combination of electrocardiographic and echocardiographic information identifies individuals prone to a progressive increase in left ventricular mass over 5 years. J. Hypertens. 2009, 27(4):861-868.
28. Kors J.A., van Herpen G., Wu J., Zhang Z., Prineas R.J., van Bemmel J.H. Validation of a new computer program for Minnesota coding. J. Electrocardiol. 1996, (29 Suppl. l):83-88.
29. Volzke H., Haring R., Lorbeer R., Wallaschofski H., Reffelmann T., Empen K., Rettig R., John U., Felix S.B., Dorr M. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 2010, 209(2):606-610.
30. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnittger I., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 1989, 2(5):358-367.
31. Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981, 63(6):1391-1398.
32. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986, 57(6):450-458.
33. Teichholz L.E., Kreulen T., Herman M.V., Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am. J. Cardiol. 1976, 37(1):7-11.
34. de Simone G., Devereux R.B., Kimball T.R., Mureddu G.F., Roman M.J., Contaldo F., Daniels S.R. Interaction between body size and cardiac workload: influence on left ventricular mass during body growth and adulthood. Hypertension 1998, 31(5):1077-1082.
35. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005, 18(12):1440-1463.
36. Royston P., Ambler G., Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int. J. Epidemiol. 1999, 28(5):964-974.
37. VanderWeele T.J., Knol M.J. A tutorial on interaction. Epidemiol. Method 2014, 3(1):33-72.
38. Kew M.C. Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 2000, 355(9204):591-592.
39. Makar G.A., Weiner M.G., Kimmel S.E., Bennett D., Burke A., Yang Y.X., Han X., Sellers K., Nessel L., Lewis J.D. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008, 17(1):43-51.
40. Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin. Chem. 1978, 24(11):1971-1979.
41. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 2007, 27(12):2729-2735.
42. Weikert C., Drogan D., di Giuseppe R., Fritsche A., Buijsse B., Nothlings U., Willich S.N., Berger K., Boeing H. Liver enzymes and stroke risk in middle-aged German adults. Atherosclerosis 2013, 228(2):508-514.
43. Targher G., Byrne C.D. Circulating markers of liver function and cardiovascular disease risk. Arterioscler. Thromb. Vasc. Biol. 2015, 35(11):2290-2296.
44. Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J., Hammer S., Romijn J.A., de Roos A., Lamb H.J. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2008, 52(22):1793-1799.
45. Fox C.S., Gona P., Hoffmann U., Porter S.A., Salton C.J., Massaro J.M., Levy D., Larson M.G., D'Agostino R.B., O'Donnell C.J., et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation 2009, 119(12):1586-1591.
46. Thanassoulis G., Massaro J.M., O'Donnell C.J., Hoffmann U., Levy D., Ellinor P.T., Wang T.J., Schnabel R.B., Vasan R.S., Fox C.S., et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ. Arrhythm. Electrophysiol. 2010, 3(4):345-350.
47. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., Tracy R.P., Van Wagoner D.R., Psaty B.M., Lauer M.S., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108(24):3006-3010.
48. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104(24):2886-2891.
49. Guo Y., Lip G.Y., Apostolakis S. Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 2012, 60(22):2263-2270.
50. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., Mullen K.D., Cooper J.N., Sheridan M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123(3):745-750.